Menu ×


Gut Microbiota Market Segmentation by Products (Probiotics, Prebiotics, Supplements, Drugs, Foods, and Others); by Application (Therapeutics, and Diagnostics); and by Indications (Autoimmune Disorder, Gastrointestinal Disorder, Diabetes, Obesity, Cancer, and Others) – Global Demand Analysis and Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Gut Microbiota Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • July 2020: Microba, an Australian microbial genetics firm, announced that it has strategically collaborated with Synlab, a German medical diagnostic services provider, to launch gut microbiome test across Latin America and Europe.
  • January 2020: The government of Canada along with other partners invested USD 18 million for the research and development of microbiome therapeutics.   

Global Gut Microbiota Market Highlights 2022-2030

The global gut microbiota market is expected to register a high CAGR of ~23% during the forecast period, i.e., 2022-2030. Extensive research associated with human gut microbiome therapy and growing investments in the development of advanced treatment methodologies is expected to fuel the progress of this market in the near future. The growth of the market can also be attributed to factors such as the increasing awareness regarding the development of human microbiome therapeutics by major market players and the rising occurrence of chronic diseases such as diabetes, cancer and neurological disorders on a global level. According to the International Diabetes Federation (IDF) data, approximately 463 million adults aged between 20-79 years were suffering from diabetes in 2019, and by 2045 the number is expected to increase to 700 million. Additionally, the rising initiatives by private organizations and government agencies to collaborate for the development of gut microbiome products are expected to offer ample growth opportunities to the global gut microbiota market over the forecast period.


The market is segmented based on products into probiotics, prebiotics, supplements, drugs, foods, and others, out of which, the probiotics segment is anticipated to grab the largest share by the end of 2030 on account of increasing awareness regarding health & fitness among individuals and growing R&D activities to develop effective probiotics by major manufacturers in the market.  Moreover, increasing focus and initiatives of regulatory bodies towards medical tourism globally are also expected to contribute to the development of the market segment in the upcoming years. Furthermore, on the basis of application, the therapeutics segment held the largest share in the global gut microbiota market on the back of growing investments for the development of microbiome-based therapies around the world. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Gut Microbiota Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is expected to grow at the highest CAGR over the forecast period owing to the growing consciousness about gut microbiota therapies and rising prevalence of diabetes, cancer, cardiovascular diseases, and neurological disorders in the region. Furthermore, the market in North America is evaluated to hold the largest share in terms of revenue during the forecast period, on the back of growing government emphasis on the manufacture of premium quality gut microbiome products, accompanied by the presence of leading service providers in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global gut microbiota market on account of its proven success in terms of therapy development and a high occurrence of chronic diseases in the region. As per the Organisation for Economic Cooperation and Development (OECD) analysis, approximately 32.3 million adults in the European Union were diagnosed with diabetes in the year 2019.


The global gut microbiota market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global gut microbiota market includes the following segments:

By Products

  • Probiotics
  • Prebiotics
  • Supplements
  • Drugs
  • Foods
  • Others

By Application

  • Therapeutics
  • Diagnostics

By Indications

  • Autoimmune Disorders
  • Gastrointestinal Disorder
  • Diabetes
  • Obesity
  • Cancer
  • Others

Growth Drivers

  • Rising Development of Gut Microbiome Therapeutics
  • Increasing Chronic Disease Prevalence in the World


  • Poor Understanding of Gut Microbiome Products in Underdeveloped Countries

Top Featured Companies Dominating the Market

  •  ViThera Pharmaceuticals, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Enterome SA
  • Ferring B.V.
  • Second Genome
  • Synlogic Inc
  • Vedanta Biosciences, Inc.
  •  Seres Therapeutics, Inc.
  • AOBiome LLC
  • Axial Biotherapeutics, Inc. 




Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved